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Acute graft-versus-host-disease (aGVHD) is a major complication of allogeneic hematopoietic stem cell
transplantation (HSCT). The purpose of this study was to characterize the oral features associated with aGVHD
in patients who underwent HSCT between 1995 and 2010 and developed prominent oral aGVHD. Data was
collected from patient medical records and analyzed descriptively. Twenty-one cases were identiﬁed, of
which 5 (24%) demonstrated only oral features; the remaining 16 had variable involvement of skin (n ¼ 14),
liver (n ¼ 7), and gut (n ¼ 5). The median time to onset of any sign of aGVHD was 22 days (range, 8 to
154 days), and that for onset of oral aGVHD was 35 days (range, 11 to 159 days). Sites affected by nonspeciﬁc
erythema and ulcerations included buccal mucosa (19 of 21; 90%) tongue (18 of 21; 86%; dorsum in 8), labial
mucosa (16 of 21; 76%), palatal mucosa (15 of 21; 71%; hard palate in 7), and ﬂoor of mouth (7 of 21; 33%).
Eight cases (38%) presented with lip ulceration and crusting. In addition to systemic therapies, topical so-
lutions of dexamethasone, tacrolimus, and morphine were used for ancillary support. Oral features of aGVHD
may be the initial manifestation and include nonspeciﬁc erythema and ulcerations of keratinized and non-
keratinized mucosa and lips. Intensive topical therapies may help reduce symptoms and promote healing.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION conditioning regimen intensity, and GVHD prophylaxis
Acute graft-versus-host disease (aGVHD) is a major
complication of allogeneic hematopoietic stem cell trans-
plantation (HSCT) that develops when transplanted donor
T cells mount an alloimmune response against recipient
(host) tissues, resulting in tissue damage, morbidity, and, in
severe cases, death [1]. Based on the National Institutes of
Health consensus criteria, aGVHD is deﬁned as either clas-
sical aGVHD, occurring within 100 days after transplantation,
or persistent, recurrent, or late aGVHD, typically occurring
beyond dayþ100 during withdrawal of immune suppression
and associated with poorer outcomes [2]. The incidence,
timing, and severity of aGVHD are inﬂuenced by several
clinical factors, including donorerecipient HLA matching,
stem cell source, number of T cells in the donor graft,dgments on page 1720.
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14.06.031regimen [3,4]. Despite prophylaxis, aGVHD develops in up to
30% to 50% of allogeneic HSCTs [4,5].
Oral features developing in the context of aGVHD have
been reported infrequently [6-13]. This is in stark contrast to
conditioning regimeneassociated oral mucositis and oral
chronic GVHD (cGVHD), both of which are commonly
encountered in the context of allogeneic HSCT and have been
extensively characterized in the literature [12,14,15]. Clinical
characteristics of the oral features attributed to aGVHD have
been reported as generalized mucosal erythema and pesu-
domembranous ulcerations, but also with features more
suggestive of cGVHD, such as lichenoid hyperkeratotic stri-
ations [1,11,16]. The objective of the present study was to
characterize a cohort of patients with oral features associated
with aGVHD with respect to clinical ﬁndings, management,
and outcomes.METHODS
A retrospective medical records review was conducted of patients who
underwent allogeneic HSCT at Dana-Farber/Brigham and Women’s Cancer
Center between 1995 and 2010 and were subsequently diagnosed with oralTransplantation.
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Oral mucosa Nonspeciﬁc erythema and ulcerations that can affect




Oral lesions typically developing in association with
classical aGVHD features (eg, skin, liver, gut)
Mucositis Complete resolution of oral ulcerations secondary to
conditioning regimen, if present, before onset of oral
aGVHD lesions
HSV Viral culture negative, ongoing acyclovir prophylaxis
Engraftment Two consecutive days with ANC >500
Table 2
Characteristics of the 21 Patients with Oral aGVHD
Characteristic Value
Median age (range) 49 (21-65)
Male sex, n (%) 14 (67)
Disease, n (%)
Acute myelogenous leukemia 7 (33)
Acute lymphoblastic leukemia 4 (19)
Chronic myelogenous leukemia 4 (19)
Myelodysplastic syndrome 3 (14)
Myeloproliferative disorder 2 (10)
Multiple myeloma 1 (5)
Donor type, n (%)
Matched related donor 11 (52)
Matched unrelated donor 9 (43)
Mismatched unrelated donor 1 (5)
Conditioning regimen intensity, n (%)
Myeloablative 15 (71)
Reduced intensity 6 (29)
Graft source, n (%)
Peripheral blood stem cells 14 (67)
Bone marrow 7 (33)
GVHD prophylaxis, n (%)
Tacrolimus/methotrexate 6 (33)
Methotrexate/cyclosporine A 6 (33)
Sirolimus/tacrolimus/methotrexate 2 (12)
Sirolimus/mycophenolate mofetil 1 (6)
Sirolimus/tacrolimus 1 (6)
Bortezomib/tacrolimus/methotrexate 1 (6)
T cell depleted 1 (6)
Not available 3 (14)
Days to ANC >500, median (range) 14 (11-50)
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consultation service at Dana-Farber/Brigham and Women’s Cancer Center.
This study was approved by the Dana-Faber/Harvard Cancer Center Insti-
tutional Review Board. Owing to the study’s retrospective nature, patient
consent was not obtained.
Transplantation-related data collected included primary diagnosis for
HSCT, donor information (including age and sex), graft source, conditioning
regimen, GVHD prophylaxis regimen, and mucositis history. With respect to
GVHD, data collected included day of onset of aGVHD, day of onset of oral
lesions, target organ involvement, highest aGVHD grade, systemic immu-
nosuppressive therapy, oral ancillary therapy, subsequent development of
oral cGVHD, and survival at day þ100 post-transplantation.
aGVHDwas graded clinically according to consensus or the International
Bone Marrow Transplant Registry (IBMTR) Severity Index Systems scale
[17,18]. Each target organ was staged from 0 to 4, and an overall aGVHD
grade of 0 to IV was determined. Patients with aGVHD limited to the oral
cavity were considered grade 0, because the consensus and IBMTR scales do
not recognize the oral cavity as a target organ. aGVHD was further classiﬁed
according to the National Institutes of Health criteria [2].
Oral aGVHD was deﬁned as the onset of oral mucosal erythema and
ulcerations in the context of engraftment (deﬁned as 2 consecutive days
with an absolute neutrophil count [ANC] >500) and aGVHD involvement
of classical target organs (Table 1). Biopsy analysis of the involved oral
mucosa was not performed in all cases, typically when the diagnosis of
aGVHD was not already established. All patients were started on standard
acyclovir prophylaxis on admission for HSCT, and viral cultures were
obtained from all patients at the time of onset of oral aGVHD lesions. In
patients who had developed conditioning regimeneassociated oral
mucositis during HSCT, all ulcerations were required to be completely
resolved before the onset of oral aGVHD lesions. Clinical intraoral pho-
tographs were reviewed to conﬁrm objective ﬁndings collected from the
medical records.
Statistical analyses were performed using SAS version 9.2 (SAS Institute,
Cary, NC). Progression-free survival was deﬁned as the time from the date of
HSCT until the date of disease relapse, progression, or death and was
censored at the time of last contact. Overall survival was deﬁned as the time




Among the 2578 recipients of allogeneic HSCT during the
15-year study period, 21 developed oral aGVHD (Table 2).
The median age of these 21 patients was 49 years (range, 21
to 65 years), and two-thirds were male. Approximately one-
third of the patients received a reduced-intensity condi-
tioning regimen, and the majority received methotrexate
and a calcineurin inhibitor for GVHD prophylaxis. The me-
dian time from HSCT to diagnosis of aGVHD (based on any
diagnostic feature) was 22 days (range, 8 to 154 days), with
95% of recipients presenting with typical clinical features
within the ﬁrst 100 days.
Classical features of aGVHD were observed in the ma-
jority of patients, including skin (n ¼ 14), liver (n ¼ 7), and
gastrointestinal (n ¼ 5) involvement, with the majority
(14 of 21; 67%) classiﬁed as grade III-IV. Five patients
(24%) presented with oral features only and thus wereconsidered to have grade 0 aGVHD. Of the patients pre-
senting with multisystem involvement, in 3 cases the
initial site was the oral cavity (followed in each case by
skin). Except for these 3 patients, and the 5 patients with
oral features only, all other patients developed oral fea-
tures after being diagnosed with aGVHD and started on
systemic corticosteroid therapy (see below). Oral muco-
sitis preceded the onset of aGVHD in approximately
one-half of the patients (11 of 21; 52%), with complete
resolution of oral ulcerations in all cases before the onset
of aGVHD. All patients received acyclovir prophylaxis, and
all viral cultures for herpes simplex virus (HSV) were
negative (data not shown). No patient had any other
identiﬁed infection (eg, cytomegalovirus reactivation,
oropharyngeal candidiasis).Oral aGVHD Features
The median time from HSCT to diagnosis of oral aGVHD
was 35 days (range, 11 to 159 days). Oral lesions were
generally characterized as extensive, irregular nonspeciﬁc
erythema and ulcerations of the keratinized and non-
keratinized mucosa (Figure 1). Lichenoid striations typical
of cGVHD were not observed. Taking all cases into consid-
eration, the buccal mucosa, tongue (ventrolateral and
dorsum), labial mucosa, and hard and soft palates were
variably affected; no gingival involvement was noted
(Table 3). Eight patients presented with prominent lip ul-
ceration with crusting that typically extended beyond the
vermillion border (Figure 2). Except for 1 patient who
experienced xerostomia and severe salivary gland hypo-
function, xerostomia was not reported by any other patient.
One patient developed asymptomatic palatal superﬁcial
mucoceles.
Oral mucosal biopsy specimens were obtained in 4
patients. Three of these biopsy specimens showed mucosal
Figure 1. Oral aGVHD presenting with diffuse ulceration of the ventrolateral
tongue, as well as ulceration and crusting of the lips.
Figure 2. Oral aGVHD with marked ulceration, bleeding, and crusting of the
lips, as well as intraoral ulcerations and thick mucous secretions.
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epithelium varied in thickness and presented variable fea-
tures of dyskeratosis and reactive atypia. All cases exhibited
acute and chronic inﬂammation within the lamina propria.
Immunohistochemical studies for HSV and cytomegalovirus
were negative.
Management and Outcomes
All patients were treated with a calcineurin inhibitor
(cyclosporine or tacrolimus) and high-dose corticosteroids
(eg, 1 to 2 mg/kg). Some patients were managed with addi-
tional systemic agents, including sirolimus, mycophenolate
mofetil, and denileukin diﬁtox, and extracorporeal photo-
pheresis. In addition to systemic immunosuppressive ther-
apy, patients were started on an oral ancillary regimen
consisting of topical high-potency corticosteroids (dexa-
methasone or compounded clobetasol solutions) andTable 3
Clinical Features of the 21 Patients with Oral aGVHD
Feature Value
Sites of GVHD, n (%)*




Days to aGVHD, median (range) 22 (8-154)
Days to oral aGVHD, median (range) 35 (11-159)
GVHD grade, n (%)





Site of ulcerations, n (%)*
Buccal mucosa 19 (90)
Tongue, any surface 18 (86)
Tongue dorsum 8 (38)
Labial mucosa 16 (76)
Palate 15 (71)
Hard palate 7 (33)
Floor of mouth 7 (33)
Lips 8 (38)
Salivary gland disease, n (%)
Hypofunction/xerostomia 1 (5)
Superﬁcial palatal mucoceles 1 (5)
* Patients could have multiple sites of involvement.tacrolimus (ointment and compounded solution). Cortico-
steroid and tacrolimus solutions were used alone or in
combination (ie, corticosteroid/tacrolimus; n ¼ 4) as a 5-
minute swish-and-spit rinse, 2 to 4 times daily. Lip involve-
ment was managed with tacrolimus ointment and clobetasol
gel, applied 2 to 3 times daily. Morphine solution as an
analgesic swish-and- spit rinse was prescribed for 3 patients
receiving concurrent systemic opioid therapy.
Sixteen patients (76%) survived beyond day þ100 post-
HSCT, and 5 patients (24%) survived longer than 1 year.
Four of the patients who survived beyond day þ100 devel-
oped cGVHD. One of these 4 patients, who had been previ-
ously treated for Hodgkin lymphoma and underwent HSCT
for secondary myelodysplastic syndrome, subsequently
developed squamous cell carcinoma of the buccal mucosa
approximately 17 months after HSCT. Seventeen patients
died, with 4 experiencing relapse before death. The 1-year
overall survival and progression-free survival estimates
were 7% (95% conﬁdence interval, <1% to 26%) and 7% (95%
conﬁdence interval, <1% to 27%), respectively.DISCUSSION
This study represents the largest series of patients with
oral manifestations of aGVHD and the most systematically
detailed report describing its associated clinical features to
date. Oral mucosal disease was typically widespread and
very painful, often extending from the vermillion of the lips
to the soft palate. Of note, 14 of the 17 patients (82%) with
classical features had grade III-IV aGVHD, suggesting that
oral features may be associated with the most severe phe-
notypes. In addition, the median day of onset was nearly
2 weeks later than seen in other areas of involvement, sug-
gesting that except for cases limited to the oral cavity, oral
involvement typically develops after initiation of steroid
therapy and in the context of an established diagnosis. The
case deﬁnition proposed in this study identiﬁed all but 5
patients who presented only with oral features that were
otherwise consistent with those observed in associationwith
systemic manifestations of aGVHD. Although we were not
able to deﬁnitively conﬁrm that these 5 cases were mani-
festations of aGVHD, the clinical characteristics were other-
wise identical to the cases that presented with classical
involvement of other organs, with no other reasonable
clinical diagnosis (eg, sirolimus-associated oral ulcerations or
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single organ involvement (eg, skin only), the possibility that
this also can occur with only oral mucosal involvement, even
if infrequent [17,18], must be considered.
Several previous reports have described variable oral
features associated with aGVHD [6-13]. Barrett and Billous
[6] reported 5 patients with oral and systemic aGVHD
involvement (skin, liver, gut) in which oral lesions presented
between 3 and 31 days after onset of systemic features, from
day þ21 to day þ43. The oral features were described as ﬁne
papular, reticular, or lichenoid, as well as ulcerative/des-
quamative changes throughout the oral mucosa. Berkowitz
et al. [7] described “recurrent stomatitis” in 5 of 25 pediatric
patients who developed generalized aGVHD that presented
approximately 1 week after complete resolution of condi-
tioning regimeneassociated oral mucositis, characterized by
diffuse intraoral and lip ulcerations. Dahllöf et al. [8]
described oral features associated with aGVHD lesions in 2
children that developed concurrently with skin lesions, with
ulcerations of the buccal mucosa and tongue. Dreizen et al.
[10] reported aGVHD in 4 of 12 patients, all of whom
developed diffuse painful oral ulcers in association with
classical systemic features [10]. Schubert and Sullivan [12]
reported several cases in which oral features preceded the
onset of systemic aGVHDmanifestations by up to 5 to 6 days.
It is possible that descriptions of white/lichenoid changes
represent “overlap syndrome” in which features of both
aGVHD and cGVHD can be seen [2]. Of note, although these
changes were not observed in the present series, after the
completion of this study, a case of oral aGVHD (meeting the
proposed guidelines) was evaluated by our consultation
service with mild hyperkeratotic reticulated areas of the
tongue dorsum, in addition to more typical ulcerations of the
bilateral buccal mucosa and ventrolateral tongue.
Optimal management of oral manifestations of aGVHD
has not been established. Berkowtiz et al. [7] reported that
the oral lesions typically resolved rapidly after initiation of
systemic corticosteroid therapy. In the present case series, in
some cases the onset of oral features did not occur until after
initiation of systemic steroid therapy, but in all cases these
features resolved in the context of prolonged high-dose
systemic steroid therapy. Schubert and Sullivan [12] noted
that topical steroid applications appeared to help reduce the
severity and duration of oral lesions associated with aGVHD,
although the speciﬁc formulations and regimens were not
described.
In the absence of available guidelines for management,
we generally followed the principles of oral cGVHD man-
agement [14]. Most patients were treated with topical high-
potency corticosteroids (dexamethasone or compounded
clobetasol solutions) and tacrolimus (ointment and com-
pounded solution), which seemed to provide clinical beneﬁt
[20]. In cases of severe pain that was uncontrolled by sys-
temic opioids, topical morphine solution appeared to be
effective in managing symptoms [21,22].
This study had several limitations. Even though our study
group is the largest series of patients with oral features of
aGVHD reported to date, the sample size was still relatively
small. These 21 cases were observed over a 15-year period
during which 2578 allogeneic HSCTs were performed at our
center and 325 recipients developed grade III-IV aGVHD
(data not shown). Moreover, such features as lichenoid hy-
perkeratotic changes that were described in previous reports
were not observed in our series [6,12]. Data were collected
retrospectively, and in some cases clinical descriptions mighthave been incomplete or inaccurate. Although biopsy speci-
mens were only obtained in select cases, given the nonspe-
ciﬁc histopathologic features, the extent to which this
evaluation might be beneﬁcial in supporting or rejecting the
diagnosis of oral aGVHD is unclear.
Although apparently infrequent, oral involvement in the
context of aGVHD can be clinically severe and must be
distinguished from other oral conditions, especially recru-
descent HSV. Based on our ﬁndings as well as previous re-
ports, it appears that in most cases, oral features present in
the context of multisystem involvement and typically as a
later manifestation; however, oral lesions may present early
or, we believe, rarely as the sole manifestation. Management
should include modiﬁed diet (eg, soft bland foods and liq-
uids, as tolerated) and intensive topical immunosuppressive
therapy until there is adequate resolution of signs and
symptoms. Future studies may better deﬁne the true inci-
dence of oral manifestations associated with aGVHD and its
signiﬁcance with respect to prognosis and outcomes.ACKNOWLEDGMENTS
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